Supplementary Figure S3 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142953

2024-01-01

Abstract:Supplementary Figure S3. FBXO38 knockout does not affect spleen NK cell development and effector function

What problem does this paper attempt to address?

Supplementary Figure S4 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142950

2024-01-01

Abstract:Supplementary Figure S4. FBXO38 does not affect NK cell trafficking
Supplementary Figure S1 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142959

2024-01-01

Abstract:Supplementary Figure S1. Down regulation of FBXO38 in IT NK cells
Supplementary Figure S8 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142938

2024-01-01

Abstract:Supplementary Figure S8. NK-92 cells with FBXO38 overexpression show enhanced antitumor activity in vivo
Supplementary Figure S7 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142941

2024-01-01

Abstract:Supplementary Figure S7. FBXO38 promotes human NK-92 cell proliferation in vitro
Supplementary Figure S2 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142956

2024-01-01

Abstract:Supplementary Figure S2. Tumor grown faster in cKO mice than Ncr1Cre/+ mice
Supplementary Figure S6 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142944

2024-01-01

Abstract:Supplementary Figure S6. FBXO38 deficiency increases the expression of suppressors of cell cycle program in TINK cells
Supplementary Table 1 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.27142935

2024-01-01

Abstract:Supplemental Table 1. Antibodies used for flow cytometry in this study
Data from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.c.7474596

2024-01-01

Abstract:Abstract Natural killer (NK) cells are the main innate antitumor effector cells but their function is often constrained in the tumor microenvironment. It has been reported that the E3 ligase FBXO38 accelerates PD-1 degradation in tumor-infiltrating T cells to unleash their cytotoxic function. In this study, we found that the transcriptional levels of FBXO38 in intratumoral NK cells of patients with cancer and tumor-bearing mice were significantly lower than in peritumoral NK cells. Conditional knockout of FBXO38 in NK cells accelerated tumor growth and increased tumor metastasis. FBXO38 deficiency resulted in impaired proliferation and survival of tumor-infiltrating NK (TINK) cells. Mechanistically, FBXO38 deficiency enhanced TGF-β signaling, including elevating expression of Smad2 and Smad3, which suppressed expression of the transcription factor Eomes and further reduced expression of surface IL15Rβ and IL15Rγc on NK cells. Consequently, FBXO38 deficiency led to TINK cell hyporesponsiveness to IL15. Consistent with these observations, FBXO38 mRNA expression was positively correlated with the proliferation of TINK cells in multiple human tumors. To study the therapeutic potential of FBXO38, mice bearing human tumors were treated with FBXO38 overexpressed human primary NK cells and showed a significant reduction in tumor size and prolonged survival. In conclusion, our results suggest that FBXO38 sustains NK-cell expansion and survival to promote antitumor immunity and have potential therapeutic implications as they suggest FBXO38 could be harnessed to enhance NK cell–based cancer immunotherapy.
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.CIR-23-1061

2024-10-01

Abstract:Natural killer (NK) cells are the main innate antitumor effector cells but their function is often constrained in the tumor microenvironment. It has been reported that the E3 ligase FBXO38 accelerates PD-1 degradation in tumor-infiltrating T cells to unleash their cytotoxic function. In this study, we found that the transcriptional levels of FBXO38 in intratumoral NK cells of patients with cancer and tumor-bearing mice were significantly lower than in peritumoral NK cells. Conditional knockout of FBXO38 in NK cells accelerated tumor growth and increased tumor metastasis. FBXO38 deficiency resulted in impaired proliferation and survival of tumor-infiltrating NK (TINK) cells. Mechanistically, FBXO38 deficiency enhanced TGF-β signaling, including elevating expression of Smad2 and Smad3, which suppressed expression of the transcription factor Eomes and further reduced expression of surface IL15Rβ and IL15Rγc on NK cells. Consequently, FBXO38 deficiency led to TINK cell hyporesponsiveness to IL15. Consistent with these observations, FBXO38 mRNA expression was positively correlated with the proliferation of TINK cells in multiple human tumors. To study the therapeutic potential of FBXO38, mice bearing human tumors were treated with FBXO38 overexpressed human primary NK cells and showed a significant reduction in tumor size and prolonged survival. In conclusion, our results suggest that FBXO38 sustains NK-cell expansion and survival to promote antitumor immunity and have potential therapeutic implications as they suggest FBXO38 could be harnessed to enhance NK cell-based cancer immunotherapy.
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL-15R Signaling

Yongjing Shi,Xiaodong Zheng,Hui Peng,Chenqi Xu,Rui Sun,Zhigang Tian,Haoyu Sun,Xianwei Wang

DOI: https://doi.org/10.1158/2326-6066.cir-23-1061

IF: 10.1

2024-01-01

Cancer Immunology Research

Abstract:This study reveals that FBXO38 enhances NK cell-mediated antitumor immunity by maintaining IL15 signal strength. FBXO38 overexpressed human NK cells exert greater therapeutic efficacy in xenograft mouse models. Natural killer (NK) cells are the main innate antitumor effector cells but their function is often constrained in the tumor microenvironment. It has been reported that the E3 ligase FBXO38 accelerates PD-1 degradation in tumor-infiltrating T cells to unleash their cytotoxic function. In this study, we found that the transcriptional levels of FBXO38 in intratumoral NK cells of patients with cancer and tumor-bearing mice were significantly lower than in peritumoral NK cells. Conditional knockout of FBXO38 in NK cells accelerated tumor growth and increased tumor metastasis. FBXO38 deficiency resulted in impaired proliferation and survival of tumor-infiltrating NK (TINK) cells. Mechanistically, FBXO38 deficiency enhanced TGF-beta signaling, including elevating expression of Smad2 and Smad3, which suppressed expression of the transcription factor Eomes and further reduced expression of surface IL15R beta and IL15R gamma c on NK cells. Consequently, FBXO38 deficiency led to TINK cell hyporesponsiveness to IL15. Consistent with these observations, FBXO38 mRNA expression was positively correlated with the proliferation of TINK cells in multiple human tumors. To study the therapeutic potential of FBXO38, mice bearing human tumors were treated with FBXO38 overexpressed human primary NK cells and showed a significant reduction in tumor size and prolonged survival. In conclusion, our results suggest that FBXO38 sustains NK-cell expansion and survival to promote antitumor immunity and have potential therapeutic implications as they suggest FBXO38 could be harnessed to enhance NK cell-based cancer immunotherapy.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494754

2023-01-01

Abstract:IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Ли Шен,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22490453.v1

2023-01-01

Abstract:EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Zhiguang Li,Jing Jiang,Zibing Wang,Jinhua Zhang,Mingjie Xiao,Chunhui Wang,Yu Lu,Zhihai Qin

DOI: https://doi.org/10.1158/0008-5472.22373513

2023-01-01

Abstract:Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis
Supplementary Figure 3 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells

Magali Terme,Evelyn Ullrich,Laetitia Aymeric,Kathrin Meinhardt,Jérôme D. Coudert,Mélanie Desbois,François Ghiringhelli,Sophie Viaud,Bernard Ryffel,Hideo Yagita,Lieping Chen,Salaheddine Mécheri,Gilles Kaplanski,Armelle Prévost-Blondel,Masashi Kato,Joachim L. Schultze,Eric Tartour,Guido Kroemer,Mariapia Degli-Esposti,Nathalie Chaput,Laurence Zitvogel

DOI: https://doi.org/10.1158/0008-5472.22391022

2023-01-01

Abstract:PDF file - 119K, Kit signaling is not involved in Kit+ NK cell differentiation and survival
Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Zhiguang Li,Jing Jiang,Zibing Wang,Jinhua Zhang,Mingjie Xiao,Chunhui Wang,Yu Lu,Zhihai Qin

DOI: https://doi.org/10.1158/0008-5472.22373516

2023-01-01

Abstract:Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis
Supplementary Figure 5 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression

Shinan Li,Rui Sun,Yongyan Chen,Wei H,Zhigang Tian

DOI: https://doi.org/10.1158/0008-5472.22407831.v1

2023-01-01

Abstract:S. Fig. 5. IL-18 silencing inhibits MDSC accumulation and restores T cell function.
Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Zhiguang Li,Jing Jiang,Zibing Wang,Jinhua Zhang,Mingjie Xiao,Chunhui Wang,Yu Lu,Zhihai Qin

DOI: https://doi.org/10.1158/0008-5472.22373519

2023-01-01

Abstract:Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis
Supplementary Figure S3 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Chengcheng Deng,Yuxin Lin,Xue-Kang Qi,Guangcun He,Yuchen Zhang,Hao-Jiong Zhang,Mingwei Xu,Feng Qian,Jin‐Xin Bei,Yi‐Xin Zeng,Feng Li

DOI: https://doi.org/10.1158/0008-5472.22419515.v1

2023-01-01

Abstract:Supplementary Figure S3 from TNFRSF19 Inhibits TGFβ Signaling through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Supplementary Figure S3 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S4 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S1 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S8 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S7 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S2 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Figure S6 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Supplementary Table 1 from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

Data from the E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling

The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL-15R Signaling

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure 3 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells

Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure 5 from TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression

Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure S3 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis